Carcinoma Non-small-cell Lung
📧 Sign up to get email alerts when something new happens for Carcinoma Non-small-cell Lung.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2021-12-14EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.
The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.
-
EMA withdrawal · 2021-11-25EMA Withdrawn: Equidacent (bevacizumab) — Centus Biotherapeutics Europe Limited
Equidacent (bevacizumab) has been withdrawn from the market in the European Medicines Agency record.
-
EMA withdrawal · 2019-10-15EMA Withdrawn: Taxespira (previously Docetaxel Hospira UK Limited ) (docetaxel trihydrate) — Hospira UK Limited
The EMA withdrew Taxespira (docetaxel trihydrate) from the market for multiple cancer indications including stomach, prostate, breast, head …
-
EMA withdrawal · 2016-09-29EMA Application withdrawn: Docetaxel SUN — Sun Pharmaceutical Industries Europe B.V.
The EMA withdrew the application for Docetaxel SUN by Sun Pharmaceutical Industries Europe B.V. for multiple cancer indications.
-
EMA withdrawal · 2012-06-14EMA Withdrawn: Docefrez (docetaxel) — Sun Pharmaceutical Industries Europe B.V.
Withdrawn EMA entry for Docefrez (docetaxel) by Sun Pharmaceutical Industries Europe B.V.; listed indications include stomach neoplasms, ade…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2009-10-30EMA Application withdrawn: Zactima (vandetanib) — AstraZeneca
The EMA withdrew the application for Zactima (vandetanib) by AstraZeneca for non-small cell lung carcinoma.
-
EMA withdrawal · 2009-09-23EMA Application withdrawn: Opaxio — CTI Life Sciences Ltd
The EMA application for Opaxio by CTI Life Sciences Ltd was withdrawn.